Partnership / Collaboration · GCC · Announced 3 Jun 2026
M42 → Arcera Life Sciences
M42 and Arcera Life Sciences signed a non-exclusive MoU to use Abu Dhabi genomics data for rare and genetic disease therapy development, clinical trials, biobanking and AI in life sciences.
Parties: M42 (United Arab Emirates) → Arcera Life Sciences (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- Abu Dhabi, UAE
- Therapeutic area
- Rare / Orphan
- Assets
- Genomics data; Cell and gene therapies; Biobanking
- Announced
- 3 Jun 2026
Our analysis
Why this matters
On 3 June 2026, Abu Dhabi-based M42 and Arcera Life Sciences announced a strategic, non-exclusive memorandum of understanding to advance biopharma localisation, clinical development and healthcare innovation in Abu Dhabi. Arcera will use M42 genomics data to assess the prevalence of specific genetic and rare diseases. The MoU has four pillars: genomics-informed therapy development, including cell and gene therapies; faster clinical development, including late-phase trials and evidence generation; biobanking, stem cell and regenerative medicine using the Abu Dhabi Biobank; and AI-enabled transformation across the life sciences value chain. No values or timelines were disclosed. The Department of Health – Abu Dhabi welcomed the collaboration.
For BD directors with rare-disease assets: local population genomics data is becoming a bargaining chip. Our reading is that Abu Dhabi partners will use prevalence data to decide which therapies to bring in and localise.
The full analysis is free to read with a work email on this page.
Source: Arcera / Acino release